Dominik Ruettinger

Dominik Ruettinger is a physician-scientist with over 12 years of experience in academia, having worked in both the United States and Germany.1 He currently holds the position of Global Head Research and Early Development Oncology at Bayer Pharmaceuticals.6

Career at Bayer

Ruettinger joined Bayer in December 2022 as the Global Head of Early Clinical Development Oncology.2 His role at Bayer involves overseeing early-stage development in oncology, which he describes as "where innovation begins".2 Since then, he has been promoted to his current position as SVP, Global Head Research and Early Development Oncology.

Focus Areas

Precision Oncology:: Ruettinger is actively involved in Bayer's efforts to advance precision oncology. He has shared updates about Bayer's partnerships and collaborations in this field, including:

• A partnership with Aignostics to develop next-generation precision oncology solutions3
• A strategic collaboration with NextRNA Therapeutics, which Ruettinger expressed excitement about, noting the innovation in this space4

Drug Development:: Ruettinger frequently shares updates on Bayer's progress in drug development, particularly in oncology. For example, he announced when the FDA granted Breakthrough Therapy designation to Bayer's oral, reversible tyrosine kinase inhibitor being developed for non-small cell lung cancer (NSCLC).5

Professional Approach

Ruettinger appears to be passionate about innovation in oncology and precision medicine. He regularly shares updates about Bayer's advancements and collaborations in these areas, demonstrating his engagement with the latest developments in the field. His background as a physician-scientist likely informs his approach to his role at Bayer, combining clinical knowledge with research expertise.